Investor Presentaiton
Financial Forecasts for FY2023
Financial Forecasts for FY2023 (Core Basis)
Billions of yen
Revenue
FY2022
Results
555.5
FY2023
Forecasts
Value
Change
FX
%
Cost of sales
Gross profit
SG&A expenses
176.7
378.8
305.6
R&D expenses
106.1
84.0
Other operating income and expenses
49.2
12.0
(Core basis)
Core operating profit
16.4 (62.0)
362.0 (193.5) (9.5) (34.8)
132.0 (44.7) (3.0) (25.3)
230.0 (148.8) (6.5) (39.3)
220.0 (85.6) (6.7) (28.0)
(22.1) (2.3) (20.8)
(37.2) (0.2) (75.6)
(78.4)
2.3
Expect both revenue and profit down for FY2023
Revenue: Japan (¥21.1B), North America (¥119.7B),
China (¥6.4B), Other Business (¥43.3B)
⚫ Japan will be affected by termination of sales collaboration
of Trulicity, NHI price revision
• North America will be affected by loss of exclusivity of
LATUDAⓇ, while ORGOVYX®, MYFEMBREE®,
GEMTESAⓇ will grow
⚫ China will decrease due to the growing impact of Volume-
Based Procurement application for MEROPENⓇ
⚫ Other Business will decrease due to the transfer of
subsidiaries
Non-recurring item
(93.3)
(16.0) 77.3
(negative number indicates loss)
SG&A and R&D expenses:
Operating profit
(77.0)
(78.0) (1.0)
1.3
•SG&A and R&D will decrease mainly due to the
Income tax expenses
48.8
(1.0) (49.8)
(96.7)
(80.0) 16.7
(74.5) (80.0) (5.5)
the parent
Net profit
Net profit attributable to owners of
ROE (%)
ROIC (%)
Sumitomo Pharma
(14.7%) (21.9%)
(3.9%)
(8.5%)
FX rates:
FY2022 Results
1US$ = ¥135.51, 1RMB = \19.75
FY2023 Forecasts: 1US$ = ¥130.00, 1RMB = \19.50
Combination of Group Companies in the U.S.
Other operating income and expenses (Core basis):
⚫ Sale of assets will decrease
Non-recurring item:
• Temporary expenses associated with the Combination of
Group Companies in the U.S. are expected
© Sumitomo Pharma Co., Ltd. All Rights Reserved. 11
7.4View entire presentation